Mitsui and QSimulate Partner with Chugai to Build Out QIDO for Pharma Research
Mitsui & Co. and QSimulate said on November 12 that they will work with Chugai Pharmaceutical to develop pharmaceutical research functions for QIDO, their quantum-classical hybrid computational chemistry platform.
1 source 3h ago
Reporting from 1 source: ASCII.jp.
Why it matters
The deal turns QIDO's roadmap toward functions shaped by an actual pharma user's evaluation, with the JHPC-quantum adoption giving the three companies a staged test of a classical, GPU, and quantum workflow against active pharmaceutical ingredient synthesis.
Key Facts
- Mitsui & Co. and QSimulate announced on November 12, 2026, a collaboration with Chugai Pharmaceutical on QIDO, a quantum-classical hybrid computational chemistry platform.
- A theme with Chugai Pharmaceutical as representative proposer and QSimulate as co-proposer was adopted for the JHPC-quantum test user program, with Mitsui & Co. as collaborator.
- QIDO will be implemented on the quantum-HPC integration platform, and verification will target complex chemical reactions in active pharmaceutical ingredient synthesis processes.
- The companies plan to evaluate technical feasibility, scientific validity, reproducibility, operability, and applicability to pharmaceutical research in stages.
- Functions developed under the collaboration are planned for release as general-purpose QIDO product functions for pharmaceutical and chemical companies.
A theme proposed by Chugai, with QSimulate as co-proposer and Mitsui as collaborator, was adopted for the JHPC-quantum test user program, where QIDO will run on the quantum-HPC integration platform.
The adopted theme targets active pharmaceutical ingredient synthesis, where the companies plan to verify a workflow that combines classical computation, GPU computation, and quantum computation. They will assess technical feasibility, scientific validity, reproducibility, operability, and applicability to pharmaceutical research in stages.
Functions developed under the collaboration are planned for release as general-purpose QIDO product functions, available to pharmaceutical and chemical companies beyond Chugai. The work centers on reaction mechanism analysis and reaction pathway search for the complex molecules and reactions handled in drug discovery.
Written with AI by Yomimono from the 1 cited source below, including Japanese-language reporting where cited. See our editorial policy.
Add Yomimono as a preferred source on Google